Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (NYSE: ABBV) is a pharmaceutical preparation manufacturing company that regularly issues news on its medicines, research programs, collaborations and manufacturing plans. Company communications emphasize a mission to discover and deliver medicines and solutions in key therapeutic areas such as immunology, oncology, neuroscience and eye care, as well as offerings in its Allergan Aesthetics portfolio.
News about AbbVie often covers clinical and scientific developments, particularly in oncology and blood cancers. The company has reported new data at major medical meetings, including results for investigational agents like etentamig (ABBV‑383) and PVEK, and updates on approved medicines such as EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax). Releases may detail trial outcomes, regulatory milestones, and additional indications under investigation.
Investors and observers can also find corporate and financial updates in AbbVie’s news flow, including announcements of earnings conference calls, participation in healthcare and investor conferences, and guidance-related information that aligns with its SEC filings. The company additionally highlights strategic agreements and collaborations, such as its exclusive licensing agreement with RemeGen for the PD‑1/VEGF bispecific antibody RC148 and its voluntary agreement with the U.S. administration focused on access, affordability and U.S.-based investment.
Another recurring theme in AbbVie’s news is manufacturing and investment activity. The company has announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, to expand drug delivery device manufacturing for immunology and neuroscience medicines, and has referenced multi‑year commitments to U.S. R&D and capital investments. AbbVie also publishes stories on patient- and community-focused initiatives, such as the “Second Winds” film about people living with chronic lymphocytic leukemia. For readers tracking ABBV, this news stream provides insight into the company’s research pipeline, regulatory progress, capital allocation and patient engagement efforts.
Allergan Aesthetics (NYSE: ABBV) partnered with entrepreneur Erin Lichy to share her Natrelle® breast augmentation journey on social media, aiming to normalize conversations about aesthetic surgery and support patient education.
The release highlights Natrelle®'s 50-year heritage, a 10-year clinical safety profile, implant options, and a nationwide Faces of Natrelle® testimonial program.
Haisco and AbbVie (NYSE: ABBV) entered an exclusive license agreement announced April 10, 2026, covering multiple pain compounds.
Haisco granted AbbVie global development, manufacturing, and commercialization rights excluding mainland China, Hong Kong, and Macau. Haisco will receive an upfront payment of USD $30 million, up to USD $715 million in milestones, and tiered royalties on future net sales.
Summary not available.
BOTOX Cosmetic (NYSE: ABBV) reopens applications for The Confidence Collective, running through April 29, 2026. The program will provide resources to 250 women entrepreneurs and award twenty $20,000 grants. Since 2023, the brand has awarded $1.2M to grant winners to support business growth and mentorship.
Selected cohort members will receive coaching, community access, and mentoring; grant winners will be announced this fall. Applicants must submit by April 29, 11:59 p.m. PT and agree to program terms.
Allergan Aesthetics (NYSE: ABBV) opened the new Allergan Medical Institute (AMI) Austin on April 7, 2026, its third U.S. AMI Training Center in the past year. The state-of-the-art facility offers immersive, hands-on education across facial injectables, body contouring, skincare, and regenerative medicine to advance clinical proficiency for providers.
AMI Austin emphasizes advanced injection techniques, complication management, practice development, and peer collaboration under Medical Director Dr. Saami Khalifian, supporting the company’s broader training network including Orange County and Atlanta centers.
Allergan Aesthetics (NYSE: ABBV) announced its fourth annual CoolMonth promotion running April 1–30, 2026, offering $400 off first-time CoolSculpting treatments for eligible Allē members and social giveaways up to $5,000.
CoolSculpting and CoolSculpting Elite are FDA-cleared for specific visible fat bulges and submental laxity; they are not weight-loss treatments. Entry and eligibility details apply.
Allergan Aesthetics (NYSE: ABBV) launched its fourth annual CoolMonth promotion for April 1–30, 2026, featuring a $400 discount for first-time CoolSculpting patients and Instagram giveaways up to $5,000.
Offers require Allē loyalty registration, are limited while supplies last, and CoolSculpting is described as an FDA-cleared, non‑surgical fat‑reduction treatment (not for weight loss).
AbbVie (NYSE: ABBV) will report first-quarter 2026 financial results on Wednesday, April 29, 2026, before the market opens.
The company will host a live earnings webcast and conference call at 8:00 a.m. Central time accessible via AbbVie's investor relations website, with an archived edition available later that day.
Allergan Aesthetics (NYSE:ABBV) presented four e-posters at AAD on March 30, 2026, reporting Phase 3 and real-world aesthetics findings.
Key TrenibotE results: investigational serotype E showed rapid onset (as early as 8 hours), shorter duration (2–3 weeks), consistent efficacy across three repeat open-label treatments, a consistent safety profile, and no neutralizing antibody development.
GLP-1 patient insights: 52% expressed facial concerns; 32% were new to practices; top barriers were cost (82%) and fear of unnatural results (58%).
AbbVie (NYSE: ABBV) will present 24 abstracts at the 2026 AAD Annual Meeting (March 27–31), highlighting clinical and real-world evidence across dermatology. Key data include 5-year risankizumab radiographic nonprogression (88% no progression), up to 6-year upadacitinib safety covering >9,000 patient-years, and Phase 3 vitiligo and alopecia areata results.
Findings emphasize sustained efficacy, long-term safety across age groups, quality-of-life gains (DLQI 0/1 up to 88.9%), and a late-breaking upadacitinib vitiligo abstract; supplemental FDA labeling for risankizumab in genital and scalp psoriasis was also noted.